FCGR2A and neoplasm: As discussed below, such knowledge will additionally pave the way for antibody-checkpoint targeted therapies, e.g., antibody blockade of inhibitory FcγRIIB or Fc-engineering for enhanced affinity to activating FcγR, to help boost efficacy and overcome resistance in the immune suppressed tumor microenvironment.